Vanguard Investments Australia
SPRY icon

Vanguard Investments Australia’s ARS Pharmaceuticals SPRY Stock Holding History

Vanguard Investments Australia’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$84.9K Hold
10,600
– – ﹤0.01% 2323
2026
Q1 		$85.1K Buy
+10,600
New +$102K ﹤0.01% 2309

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tyro Capital Management Miami, Florida $446M AUM 84.15% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Janney Montgomery Scott
Janney Montgomery Scott Philadelphia, Pennsylvania $51.6B AUM 27.34% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Vanguard Investments Australia's SPRY Position: Q2 2026 in Review

Vanguard Investments Australia held its ARS Pharmaceuticals (SPRY) position steady in Q2 2026 at 10,600 shares worth $84.9K. The position accounts for ﹤0.01% of the portfolio, ranked #2323.

Vanguard Investments Australia first reported a position in SPRY in Q1 2026 and has held it in 2 quarters since. The position peaked at $85.1K in Q1 2026. 192 funds tracked by Wall St. Rank hold SPRY as of Q2 2026.

  • Vanguard Investments Australia held 10,600 shares of ARS Pharmaceuticals worth $84.9K as of Q2 2026.
  • Vanguard Investments Australia left its ARS Pharmaceuticals share count unchanged in Q2 2026.
  • ARS Pharmaceuticals made up ﹤0.01% of Vanguard Investments Australia's portfolio in Q2 2026, its #2323 holding.
  • Vanguard Investments Australia first reported a position in ARS Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Investments Australia's ARS Pharmaceuticals position peaked at $85.1K in Q1 2026.
  • 192 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2026.

Based on Vanguard Investments Australia's 13F filing for Q2 2026, filed 13 Aug 2026.